In rheumatic heart disease-associated AF, rivaroxaban increased adverse vascular outcomes vs. VKA at 3 y. Lader EW. Ann Intern Med 2023;176:JC2.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Lader EW. In rheumatic heart disease-associated AF, rivaroxaban increased adverse vascular outcomes vs. VKA at 3 y. Ann Intern Med 2023;176:JC2.
PMID: 36592467